About Dxcover
Dxcover is a company based in Glasgow (United Kingdom) founded in 2016 by Matthew J Baker and Mark Hegarty. Dxcover has raised $15.45 million across 4 funding rounds from investors including Mercia, University of Strathclyde and Macmillan Cancer Support. The company has 16 employees as of January 31, 2021. Dxcover offers products and services including PANAROMIC™ Platform and DROP DRY DETECT™. Dxcover operates in a competitive market with competitors including Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
- Headquarter Glasgow, United Kingdom
- Employees 16 as on 31 Jan, 2021
- Founders Matthew J Baker, Mark Hegarty
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Dxcover Limited
- Date of Incorporation 16 May, 2016
- Jurisdiction GLASGOW, SCOTLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$15.45 M (USD)
in 4 rounds
-
Latest Funding Round
$6.2 M (USD), Series A
Feb 03, 2025
-
Investors
Mercia
& 10 more
-
Employee Count
16
as on Jan 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Dxcover
Dxcover offers a comprehensive portfolio of products and services, including PANAROMIC™ Platform and DROP DRY DETECT™.
Enables early detection of multiple cancers using AI and spectroscopy.
Facilitates liquid biopsy for cancer diagnosis through spectral analysis.
People of Dxcover
Unlock access to complete
Unlock access to complete
Funding Insights of Dxcover
Dxcover has successfully raised a total of $15.45M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $6.2 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Dxcover
Dxcover has secured backing from 11 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Mercia, University of Strathclyde and Macmillan Cancer Support.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment in science and technology is managed by Eos.
|
Locked | Locked | Locked | |
|
Venture capital fund focused on social impact companies
|
Locked | Locked | Locked | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked |
Investor details for Dxcover
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Dxcover
Investment portfolio details for Dxcover
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Dxcover
Detailed financials for Dxcover
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dxcover Comparisons
Peer comparison for Dxcover
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Dxcover
Dxcover operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
|
| Locked | Locked | Locked |
Blood-based liquid biopsy tests for multiple cancer detection are provided.
|
Detailed competitors of Dxcover
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dxcover
Complete news archive for Dxcover
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dxcover
Dxcover was founded in 2016 and raised its 1st funding round 6 years after it was founded.
Dxcover is headquartered in Glasgow, United Kingdom. It is registered at Glasgow, Scotland, United Kingdom.
Mark Hegarty is the current CEO of Dxcover. They have also founded this company.
Dxcover is a funded company, having raised a total of $15.45M across 4 funding rounds to date.
As of Jan 31, 2021, the latest employee count at Dxcover is 16.
Dxcover was founded in 2016 in Glasgow, United Kingdom, within the health technology sector. An AI-powered platform is utilized by the company, integrating novel hardware with algorithms to analyze blood samples. Early detection of brain tumors and other common cancers is facilitated through this device. Operations focus on diagnostic tools for oncology, serving medical applications in the UK and beyond.
Dxcover's top competitors include Guardant Health, Exact Sciences and Foundation Medicine.
Dxcover offers PANAROMIC™ Platform and DROP DRY DETECT™.
Dxcover has 11 investors. Key investors include Mercia, University of Strathclyde, Macmillan Cancer Support, Scottish Enterprise, and European Union.